The Company has enclosing herewith copy of newspapers advetiement of financial resulst for the quarter and yaer ended 31.03.2026.
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Krebs Biochemicals & Industries Limited has published its audited financial results for Q4 and FY ended March 31, 2026. Total income from operations increased to Rs. 881.27 lakhs in Q4 FY26 from Rs. 643.85 lakhs in Q4 FY25, and annual income rose to Rs. 4,402.08 lakhs from Rs. 2,575.79 lakhs. However, the company continues to incur losses with net loss after tax of Rs. 233.96 lakhs for Q4 and Rs. 2,693.93 lakhs for full year FY26. While losses remain significant, they have reduced compared to FY25 which had net loss of Rs. 1,693.31 lakhs. The loss per share for FY26 stands at Rs. 12.49. The equity share capital remains at Rs. 2,156.06 lakhs.
The company shows improving operational revenue but remains loss-making. Shareholders should note the continued losses despite higher revenues, indicating ongoing challenges in the business.